Glesatinib
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206506

CAS#: 936694-12-1 (free base)

Description: Glesatinib, also known as MGCD-265, is an orally bioavailable, small-molecule, multitargeted tyrosine kinase inhibitor with potential antineoplastic activity. MGCD265 binds to and inhibits the phosphorylation of several receptor tyrosine kinases (RTKs), including the c-Met receptor (hepatocyte growth factor receptor); the Tek/Tie-2 receptor; vascular endothelial growth factor receptor (VEGFR) types 1, 2, and 3; and the macrophage-stimulating 1 receptor (MST1R or RON).


Chemical Structure

img
Glesatinib
CAS# 936694-12-1 (free base)

Theoretical Analysis

MedKoo Cat#: 206506
Name: Glesatinib
CAS#: 936694-12-1 (free base)
Chemical Formula: C31H27F2N5O3S2
Exact Mass: 619.15
Molecular Weight: 619.706
Elemental Analysis: C, 60.08; H, 4.39; F, 6.13; N, 11.30; O, 7.75; S, 10.35

Price and Availability

Size Price Availability Quantity
10mg USD 350 2 Weeks
50mg USD 850 2 Weeks
Bulk inquiry

Related CAS #: 936694-12-1 (free base)   1123838-51-6 (HCl)   Glesatinib Glycolate  

Synonym: MGCD-265; MGCD 265; MGCD265; Glesatinib;

IUPAC/Chemical Name: N-((3-fluoro-4-((2-(5-(((2-methoxyethyl)amino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)carbamothioyl)-2-(4-fluorophenyl)acetamide

InChi Key: YRCHYHRCBXNYNU-UHFFFAOYSA-N

InChi Code: InChI=1S/C31H27F2N5O3S2/c1-40-13-12-34-17-20-4-8-24(36-18-20)28-16-25-30(43-28)27(10-11-35-25)41-26-9-7-22(15-23(26)33)37-31(42)38-29(39)14-19-2-5-21(32)6-3-19/h2-11,15-16,18,34H,12-14,17H2,1H3,(H2,37,38,39,42)

SMILES Code: O=C(NC(NC1=CC=C(OC2=C3C(C=C(C4=NC=C(CNCCOC)C=C4)S3)=NC=C2)C(F)=C1)=S)CC5=CC=C(F)C=C5

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Note: As of today, many vendors are selling Glesatinib (MGCD-265) as wrong structure.

Product Data:
Biological target: Glesatinib (MGCD265) is an orally active, potent MET/SMO dual inhibitor.
In vitro activity: These results suggested that glesatinib could not impact the expression and localization of P-gp. This study next tested the effects of glesatinib to the efflux functions of P-gp. Reference: Front Oncol. 2019 Apr 25;9:313. https://pubmed.ncbi.nlm.nih.gov/31106148/
In vivo activity: Glesatinib was also tested across a broader panel of tumor xenograft models and regression was also observed in the MET amplification-positive MKN-45 model, whereas only partial tumor growth inhibition (40%–80%) was observed in eight other models only expressing WT MET (Supplementary Fig. S2). Reference: Clin Cancer Res. 2017 Nov 1;23(21):6661-6672. https://pubmed.ncbi.nlm.nih.gov/28765324/

Preparing Stock Solutions

The following data is based on the product molecular weight 619.71 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Cui Q, Cai CY, Gao HL, Ren L, Ji N, Gupta P, Yang Y, Shukla S, Ambudkar SV, Yang DH, Chen ZS. Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells. Front Oncol. 2019 Apr 25;9:313. doi: 10.3389/fonc.2019.00313. PMID: 31106148; PMCID: PMC6494935. 2. Engstrom LD, Aranda R, Lee M, Tovar EA, Essenburg CJ, Madaj Z, Chiang H, Briere D, Hallin J, Lopez-Casas PP, Baños N, Menendez C, Hidalgo M, Tassell V, Chao R, Chudova DI, Lanman RB, Olson P, Bazhenova L, Patel SP, Graveel C, Nishino M, Shapiro GI, Peled N, Awad MM, Jänne PA, Christensen JG. Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models. Clin Cancer Res. 2017 Nov 1;23(21):6661-6672. doi: 10.1158/1078-0432.CCR-17-1192. Epub 2017 Aug 1. PMID: 28765324.
In vitro protocol: 1. Cui Q, Cai CY, Gao HL, Ren L, Ji N, Gupta P, Yang Y, Shukla S, Ambudkar SV, Yang DH, Chen ZS. Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells. Front Oncol. 2019 Apr 25;9:313. doi: 10.3389/fonc.2019.00313. PMID: 31106148; PMCID: PMC6494935. 2. Engstrom LD, Aranda R, Lee M, Tovar EA, Essenburg CJ, Madaj Z, Chiang H, Briere D, Hallin J, Lopez-Casas PP, Baños N, Menendez C, Hidalgo M, Tassell V, Chao R, Chudova DI, Lanman RB, Olson P, Bazhenova L, Patel SP, Graveel C, Nishino M, Shapiro GI, Peled N, Awad MM, Jänne PA, Christensen JG. Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models. Clin Cancer Res. 2017 Nov 1;23(21):6661-6672. doi: 10.1158/1078-0432.CCR-17-1192. Epub 2017 Aug 1. PMID: 28765324.
In vivo protocol: 1. Engstrom LD, Aranda R, Lee M, Tovar EA, Essenburg CJ, Madaj Z, Chiang H, Briere D, Hallin J, Lopez-Casas PP, Baños N, Menendez C, Hidalgo M, Tassell V, Chao R, Chudova DI, Lanman RB, Olson P, Bazhenova L, Patel SP, Graveel C, Nishino M, Shapiro GI, Peled N, Awad MM, Jänne PA, Christensen JG. Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models. Clin Cancer Res. 2017 Nov 1;23(21):6661-6672. doi: 10.1158/1078-0432.CCR-17-1192. Epub 2017 Aug 1. PMID: 28765324.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Padda S, Neal JW, Wakelee HA. MET inhibitors in combination with other
therapies in non-small cell lung cancer. Transl Lung Cancer Res. 2012
Dec;1(4):238-53. doi: 10.3978/j.issn.2218-6751.2012.10.08. Review. PubMed PMID:
25806189; PubMed Central PMCID: PMC4367550.


2: Belalcazar A, Azaña D, Perez CA, Raez LE, Santos ES. Targeting the Met pathway
in lung cancer. Expert Rev Anticancer Ther. 2012 Apr;12(4):519-28. doi:
10.1586/era.12.16. Review. PubMed PMID: 22500688.